8 Ago 2022 | Press release
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times’ 1000 Fastest Growing Companies in Europe for the in 2022. This rating is co-created by the Financial Times and...
25 Jul 2022 | Press release
Technophage, together with partners LX Bio, VectorB2B and FFUL is pleased to announce the signing of a new PRR Grant Agreement with the Portuguese Government, in the scope of the Mobilizing Agendas for Business Innovation in Portugal. The Bio-Hub consortium aims to...
4 Nov 2021 | Press release
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study aims to assess the safety and tolerability of this product in individuals with diabetic foot ulcers. According to the data...
